The global cloud computing in pharmaceutical market size was valued at USD 20.97 billion in 2025 and is projected to grow from USD 24.03 billion in 2026 to USD 71.49 billion by 2034, registering a CAGR of 14.6% during the forecast period from 2026 to 2034. North America dominated the cloud computing in pharmaceutical market with a market share of 41.5% in 2025.
Cloud computing in the pharmaceutical industry refers to the use of cloud-based platforms and services to store, process, and analyze data, enhancing efficiency across drug development, manufacturing, and distribution. By leveraging scalable computing power, real-time data access, and advanced analytics, pharmaceutical companies can accelerate research, clinical trials, regulatory compliance, and supply chain management. Cloud technology enables secure collaboration, AI-driven drug discovery, and cost-effective data storage, improving innovation and operational efficiency.
Download a Free Sample To learn more about this report,
Integration of Artificial Intelligence With Cloud-Based Pharmaceutical Research
The growing volume of complex scientific data is encouraging pharmaceutical researchers to combine artificial intelligence with cloud computing for drug discovery, target identification, and computational analysis. This transition provides scalable computing resources and centralized data access, allowing research teams to analyze large datasets and run AI models more efficiently across drug development workflows. For example, Pfizer and AWS reported that their cloud-based PACT initiative used AI and machine learning across 14 projects and helped save scientists up to 16,000 hours of search time annually while reducing infrastructure costs by 55%.
Adoption of Cloud-Based Clinical Trial Management Platforms
The increasing complexity of clinical studies and the need to connect data from multiple trial sources are encouraging pharmaceutical companies to adopt cloud-based platforms for clinical trial management and analysis. This transition is creating more centralized clinical data environments that support collaboration, automation, and faster access to study information across different teams and locations. For example, Merck created a clinical data layer on AWS that unifies clinical and operational data across studies, while AWS reports that its Clinical Trial Optimization Studio helped Merck reduce manual work by 70% with 90% accuracy.
Scalable Data Storage and Distributed Research Workflows Drive Market
The large volume and complexity of biomedical data create requirements for storage systems that can scale without extensive on-premises infrastructure. NIH identifies scalable cloud storage as a key resource for biomedical research, including genomics data, medical images, and other large datasets. For example, the NIH STRIDES program has supported access to more than 115 petabytes of high-value biomedical data through cloud resources, demonstrating the scale of datasets that require flexible storage capacity. This storage requirement supports procurement of cloud infrastructure, data-management services, and scalable computing resources across pharmaceutical research activities.
The use of geographically distributed research teams creates requirements for secure environments that allow researchers to access shared data and computing resources from different locations. NIH states that cloud platforms support data sharing and collaboration across research organizations while providing access to computing and storage resources without requiring large-scale local infrastructure. For example, researchers at separate pharmaceutical or academic sites can access shared genomic datasets and computational resources through controlled cloud environments during collaborative studies. FDA guidance also recognizes cloud computing as an option for retaining electronic clinical-investigation records when authenticity, integrity, confidentiality, and appropriate backup are maintained. This requirement supports cloud adoption for distributed research teams and creates continued use of shared storage, computing, and data-access services.
Data Security and Regulatory Requirements Restrain Market Expansion
Data security and privacy concerns can arise when pharmaceutical companies store sensitive patient, clinical trial, research, and intellectual property data on cloud platforms. Unauthorized access, cyberattacks, and data breaches can increase operational and compliance risks for organizations handling confidential information. These concerns can make pharmaceutical companies cautious about cloud adoption and slow market growth.
Stringent regulatory and compliance requirements can increase the complexity of using cloud platforms for pharmaceutical data and regulated processes. Companies need appropriate controls for data integrity, access management, audit trails, validation, and documentation across regulated environments. The additional compliance burden can increase implementation costs and delay the adoption of cloud computing in pharmaceutical operations.
Strategic Cloud Partnerships and Cloud-Based Pharmaceutical Manufacturing Offers Growth Opportunities
Cloud providers, pharmaceutical companies, and technology integrators can collaborate on secure infrastructure, data platforms, and specialized research environments. AWS states that 9 of the top 10 global pharmaceutical companies use AWS for data analytics and machine learning, while its life-sciences platform supports hundreds of customers, creating revenue through long-term cloud contracts, managed services, and customized solutions.
Pharmaceutical manufacturers, cloud providers, and software companies can connect production data, quality controls, batch records, and compliance workflows through cloud platforms. AWS reports that Novartis uses Insight Centers to make manufacturing-quality data available in real time, while Moderna uses AWS for a GxP-validated manufacturing environment, creating revenue through implementation services, software solutions, and recurring cloud contracts.
Cloud Migration Costs and Data Interoperability Hinders Growth
Moving pharmaceutical workloads, applications, and large datasets to cloud environments requires investment in migration services, system modernization, connectivity, and ongoing cloud resources. The U.S. Government Accountability Office reported that modernization of 11 critical legacy systems involved systems ranging from 23 to 60 years old and collectively costing about $754 million annually to operate and maintain, illustrating the scale and cost of modernizing complex legacy infrastructure. These costs can be significant for companies with complex research and manufacturing infrastructures, delaying migration projects and limiting adoption among smaller pharmaceutical organizations.
Pharmaceutical operations generate data from clinical trials, laboratories, manufacturing systems, supply chains, and research platforms using different formats and architectures. The FDA identifies data harmonization, data exchange standards, and harmonized controlled vocabularies as important areas for effective health-data exchange and analysis. Incompatible systems can therefore make data migration and integration difficult, requiring additional tools and process redesign that can slow cloud deployment and reduce expected operational benefits.
The software-as-a-service (SaaS) segment accounted for a share of 54.3% in 2025, owing to its scalability, accessibility, and widespread use for pharmaceutical data management, collaboration, research, and business operations. the growing adoption of cloud-based software solutions and increasing demand for flexible and cost-efficient IT infrastructure further strengthen the segment’s dominant position in the cloud computing in pharmaceutical market.
The platform-as-a-service (PaaS) segment is expected to grow at a CAGR of 18.3% during the forecast period, driven by increasing demand for cloud-based application development, data analytics, artificial intelligence, and digital pharmaceutical workflows. the infrastructure-as-a-service (IaaS) segment supports scalable computing, storage, and networking requirements across pharmaceutical organizations and enables flexible management of digital infrastructure.
Request Customizationto receive a tailored report.
The public cloud segment accounted for a share of 46.8% in 2025 due to its scalability, cost efficiency, and widespread accessibility across pharmaceutical organizations. the increasing adoption of cloud-based data storage, collaboration platforms, and digital pharmaceutical applications further strengthens the segment’s dominant position in the cloud computing in pharmaceutical market.
The hybrid cloud segment is expected to grow at a CAGR of 19.1% during the forecast period, fueled by increasing demand for flexible cloud environments, enhanced data security, and the ability to combine public and private cloud infrastructure. the private cloud segment supports pharmaceutical organizations requiring greater control over sensitive data, regulatory compliance, and customized IT environments.
The PMS (production management system) segment accounted for a share of 34.7% in 2025, supported by the widespread use of cloud-based production management systems for manufacturing operations, resource planning, process monitoring, and data management. the increasing need for scalable and efficient production workflows across pharmaceutical manufacturing further strengthens the segment’s dominant position in the cloud computing in pharmaceutical market.
The online sales segment is expected to grow at a CAGR of 18.5% during the forecast period, propelled by increasing adoption of digital pharmaceutical sales channels, growing e-commerce penetration, and rising demand for convenient online purchasing and order management. the EMR (electronic medical record) segment supports secure digital management and sharing of patient medical information, while the other segment includes additional cloud-based applications supporting pharmaceutical operations, data management, and digital workflows.
Speak to an Analystto discuss market opportunities.
The Middle East and Africa cloud computing in pharmaceutical market is expected to grow at a CAGR of 15.8%, supported by increasing healthcare digitalization, improving technology infrastructure, and growing investments in cloud-based pharmaceutical solutions. The UAE cloud computing in pharmaceutical market is expected to benefit from the country’s expanding digital pharmaceutical ecosystem. In June 2026, the Emirates Drug Establishment reported progress in implementing Agentic AI across pharmaceutical regulatory operations to build a more proactive and efficient pharmaceutical system, while its 2026 initiatives also include AI-driven drug efficacy design using advanced digital models to accelerate pharmaceutical research and development. These developments are expected to support greater adoption of cloud-based computing, data management, and digital platforms across pharmaceutical operations.
The Africa cloud computing in pharmaceutical market is expected to benefit from increasing digitalization of pharmaceutical production and supply chains. In 2026, WHO launched a dedicated situation analysis on the intersection of digitalization and pharmaceutical production in Africa to identify digital tools that can strengthen production, regulation, quality assurance, and pharmaceutical supply chains. WHO’s Pharma 4.0 initiative is also examining practical approaches to accelerate digitalization in local pharmaceutical manufacturing, while Africa CDC is scaling a continental public-health data platform using hybrid/cloud environments to support secure data sharing, advanced analytics, and AI-driven intelligence.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cloud computing in pharmaceutical market is expected to grow at a CAGR of 19.6%, showcasing the fastest-growing regional market, driven by rapid pharmaceutical digitalization, increasing cloud adoption, and growing investments in healthcare technology infrastructure. In Japan, the Ministry of Health, Labour and Welfare (MHLW) is advancing healthcare digitalization through cloud-based infrastructure, with its 2026 medical DX framework describing the use of cloud platforms to externalize, standardize, and share healthcare information and data, alongside efforts to promote cloud-native electronic medical record systems and cloud-to-cloud connectivity. In China, the Ministry of Industry and Information Technology (MIIT), together with six other government departments, issued the Pharmaceutical Industry Digital and Intelligent Transformation Implementation Plan (2025–2030), which encourages pharmaceutical companies to develop pharmaceutical big-data platforms and promotes high-performance cloud-computing platforms, data centers, 5G networks, and IoT infrastructure, with targets for significant digital transformation progress by 2027 and broader digital transformation coverage among large pharmaceutical enterprises by 2030.
In South Korea, the Ministry of Food and Drug Safety (MFDS) revised its Digital Medical Products approval, certification, notification, review, and evaluation regulations in July 2026, strengthening the regulatory framework for digital medical products and supporting the broader integration of digital technologies across the healthcare ecosystem. In India, the Department of Pharmaceuticals reported in its 2025–26 Annual Report that its web applications have been migrated to a cloud environment as part of its e-governance and digital infrastructure initiatives, providing a direct government example of cloud adoption within India's pharmaceutical administration ecosystem.
The Europe cloud computing in pharmaceutical market accounted for a regional share of 27.2% in 2025, supported by increasing adoption of digital pharmaceutical operations, growing demand for secure data management, and expanding use of cloud platforms across research and manufacturing. In the U.K. cloud computing in pharmaceutical market, the Government Digital Service reported in July 2026 that the country’s cloud market was worth more than £10.5 billion, with 60% of businesses using cloud services. The government is also developing national-scale cloud foundations and promoting secure cloud infrastructure, supporting the digital infrastructure needed for pharmaceutical research, data management, drug development, and manufacturing.
In the Germany cloud computing in pharmaceutical market, the Federal Ministry of Health’s GEMEINSAM DIGITAL 2026 strategy supports the secure and data-protection-compliant use of cloud services for processing health data to improve healthcare, research, and administration. The strategy also highlights AI, health-data infrastructure, and the European Health Data Space, supporting cloud adoption across pharmaceutical research and healthcare applications. Meanwhile, the France cloud computing in pharmaceutical market is supported by the Ministry of Health’s efforts to advance sovereign cloud infrastructure for health data. In 2026, the national health-data platform began transitioning toward secure sovereign hosting, with cloud providers being engaged through the Nuage Public framework to provide secure hosting for health data used by researchers, innovators, and public and private-sector projects, strengthening the cloud infrastructure supporting pharmaceutical research, clinical development, and health-data applications.
In the Germany cloud computing in pharmaceutical market, the federal ministry of health’s gemeinsam digital 2026 strategy supports the secure and data-protection-compliant use of cloud services for processing health data to improve healthcare, research, and administration. The strategy also highlights AI, health-data infrastructure, and the European Health Data Space, supporting cloud adoption across pharmaceutical research and healthcare applications. Meanwhile, the France cloud computing in pharmaceutical market is supported by the Ministry of Health’s efforts to advance sovereign cloud infrastructure for health data. In 2026, the national health-data platform began transitioning toward secure sovereign hosting, with cloud providers being engaged through the Nuage Public framework to provide secure hosting for health data used by researchers, innovators, and public and private-sector projects, strengthening the cloud infrastructure supporting pharmaceutical research, clinical development, and health-data applications.
The cloud computing in pharmaceutical market is moderately fragmented, with cloud service providers, pharmaceutical technology companies, enterprise software providers, IT service companies, data analytics firms, cybersecurity providers, and specialized healthcare technology companies competing across drug discovery, clinical trials, manufacturing, supply chain management, research, and healthcare data management applications. Established players compete primarily on cloud infrastructure scalability, data security, regulatory compliance, interoperability, data management capabilities, artificial intelligence and analytics, platform reliability, customization, integration capabilities, global infrastructure, and technical support, with leading players such as Amazon, Microsoft, IBM, Oracle, and Google estimated to account for approximately 65% of the global market based on their cloud infrastructure capabilities, pharmaceutical technology solutions, geographic presence, and competitive positioning.
Emerging and regional players within the cloud computing in pharmaceutical market ecosystem compete through cost-effective cloud solutions, specialized pharmaceutical platforms, flexible deployment models, application-specific services, localized support, rapid innovation, customized solutions, and advanced data analytics capabilities to address evolving pharmaceutical technology requirements and strengthen their market presence. These players also focus on developing specialized cloud applications, improving data security and interoperability, and providing tailored solutions for pharmaceutical workflows to differentiate their offerings and expand their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Tejas Zamde is a market research professional with over 2 years of experience in the technology, semiconductor, electronics, and automotive sectors. He specializes in market assessment, competitive intelligence, industry analysis, market sizing, demand analysis, and strategic research.
His experience includes analyzing technology trends, market dynamics, regulatory developments, supply-demand patterns, value chains, and competitive landscapes across global and regional markets. He has supported clients with opportunity assessment, customer segmentation, competitive benchmarking, and growth strategy development.
Security as a Service Market Size, Share, Growth, Analysis, 2034
Blockchain Distributed Ledger Market Size, Share, Growth, 2034
Digital Utility Market Size, Share, Growth, Analysis, 2034
Graph Analytics Market Size, Share, Growth, Analysis, Report, 2034
In-Store Analytics Market Size, Share, Growth, Analysis, 2034
Digital Twin Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com